<DOC>
	<DOCNO>NCT01420081</DOCNO>
	<brief_summary>This study investigate individual safety efficacy two dual PI3K/mTOR inhibitor patient recurrent endometrial cancer .</brief_summary>
	<brief_title>A Study Of Two Dual PI3K/mTOR Inhibitors , PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer</brief_title>
	<detailed_description>The study prematurely discontinue due lack confidence Stathmin assay patient selection criterion subsequent lack confidence efficacy signal observe . The decision terminate study make January 23 , 2014 . It note safety concern see study factor decision .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Recurrent endometrial carcinoma Disease progression follow one two line prior treatment platinum contain chemotherapy Tumor tissue available time screen PI3K analysis Adequate performance status Adequate glucose control , bone marrow , kidney , liver , heart function More 2 prior cytotoxic chemo regimens endometrial carcinoma Prior therapy agent know PI3K , mTOR AKT inhibitor Active brain metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>uterine neoplasm</keyword>
	<keyword>endometrial</keyword>
	<keyword>uterine</keyword>
	<keyword>cancer</keyword>
	<keyword>PI3K</keyword>
	<keyword>mTOR</keyword>
	<keyword>PI3K/mTOR</keyword>
	<keyword>recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>